Taro Recovering From Profit Shortage Following Branded OTC Promotions
This article was originally published in The Tan Sheet
Executive Summary
A steady increase in sales and lowering of costs in the second half of 2004 show Taro is recovering from profit shortages that stemmed in part from promotional spending on its branded OTC products, the firm says
You may also be interested in...
Taro Readies Branded OTC Exodus With ElixSure, Kerasal Divestiture
Taro's divestiture of its ElixSure cough/cold medicine and Kerasal moisturizer brands in North America to Alterna signals the firm's exit from the branded OTC drug market
Taro Readies Branded OTC Exodus With ElixSure, Kerasal Divestiture
Taro's divestiture of its ElixSure cough/cold medicine and Kerasal moisturizer brands in North America to Alterna signals the firm's exit from the branded OTC drug market
Taro Readies Branded OTC Exodus With ElixSure, Kerasal Divestiture
Taro's divestiture of its ElixSure cough/cold medicine and Kerasal moisturizer brands in North America to Alterna signals the firm's exit from the branded OTC drug market